Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011702

Enrollment

Unknown

Registered

2017-06-19

Start date

2017-07-01

Completion date

Unknown

Last updated

2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

membranous nephropathy

Interventions

mizoribine group:treated with mizoribine and steroid

cyclophosphamide group:treated with cyclophosphamide and steroid

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. pathological diagnosis of membranous nephropathy; 2. 24hr urinary protein excretion > 3.5g; 3. normal renal function; 4. aged 55 years and older; 5. No previous use of immunosuppressants (except mizoribine and cyclophosphamide); 6. Sign informed consent.;Inclusion criteria: 1. pathological diagnosis of membranous nephropathy; 2. 24hr urinary protein excretion > 3.5g; 3. normal renal function; 4. aged 55 years and older; 5. No previous use of immunosuppressants (except mizoribine and cyclophosphamide); 6. Sign informed consent.;Inclusion criteria: 1. pathological diagnosis of membranous nephropathy; 2. 24hr urinary protein excretion > 3.5g; 3. normal renal function; 4. aged 55 years and older; 5. No previous use of immunosuppressants (except mizoribine and cyclophosphamide); 6. Sign informed consent.;Inclusion criteria: 1. pathological diagnosis of membranous nephropathy; 2. 24hr urinary protein excretion > 3.5g; 3. normal renal function; 4. aged 55 years and older; 5. No previous use of immunosuppressants (except mizoribine and cyclophosphamide); 6. Sign informed consent.;Inclusion criteria: 1. pathological diagnosis of membranous nephropathy; 2. 24hr urinary protein excretion > 3.5g; 3. normal renal function; 4. aged 55 years and older; 5. No previous use of immunosuppressants (except mizoribine and cyclophosphamide); 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. secondary nephritic syndrome; 2. leukocyte reduction 3. pregnancy; 4. serious hematuria; 5. serious heart or liver disease; 6. Poor compliance.;Exclusion criteria: 1. secondary nephritic syndrome; 2. leukocyte reduction 3. pregnancy; 4. serious hematuria; 5. serious heart or liver disease; 6. Poor compliance.;Exclusion criteria: 1. secondary nephritic syndrome; 2. leukocyte reduction 3. pregnancy; 4. serious hematuria; 5. serious heart or liver disease; 6. Poor compliance.;Exclusion criteria: 1. secondary nephritic syndrome; 2. leukocyte reduction 3. pregnancy; 4. serious hematuria; 5. serious heart or liver disease; 6. Poor compliance.;Exclusion criteria: 1. secondary nephritic syndrome; 2. leukocyte reduction 3. pregnancy; 4. serious hematuria; 5. serious heart or liver disease; 6. Poor compliance.

Design outcomes

Primary

Measure	Time frame
total remission rate=complete remission rate+partial remission rate;complete remission rate;partial remission rate;	—

Secondary

Measure	Time frame
assessment of the changes of leukocyte, hemoglobin, liver function, blood electrolyte, blood glucose, serum albumin, serum creatinine, eGFR, cholesterol, triglyceride, uric acid, urine ruotine examinnation;	—

Countries

China

Contacts

Public ContactWang Xichao;Wang Xichao;Wang Xichao;Wang Xichao;Wang Xichao ;;;;

Tianjin First Central Hospital;Tianjin First Central Hospital;Tianjin First Central Hospital;Tianjin First Central Hospital;Tianjin First Central Hospital

ctxichao@outlook.com;ctxichao@outlook.com;ctxichao@outlook.com;ctxichao@outlook.com;ctxichao@outlook.com+86 15122198335;+86 15122198335;+86 15122198335;+86 15122198335;+86 15122198335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026